, ,
I.KaganH
At 6 months, the patient group treated with exenatide experienced significantly greater treatment satisfaction ( P /=65 years old) and very elderly ( 75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
17 The UKPDS also demonstrated that metformin is associated with less weight gain and fewer hypoglycemic episodes compared with sulfonylureas
Aside from the numbers on the scale, improvements in health markers associated with weight-related conditions, such as lower blood pressure, improved cholesterol levels, and better control of blood sugar levels in individuals with type 2 diabetes, are also significant indicators
By Donna Monthei, RDN, LD | Originally Published: May 7, 2025 | Medically Reviewed on June 18, 2026 First things first, lets do a quick recap on what these GLP-1 (glucagon-like peptide-1) receptor agonists actually do